Prednisolone (NSC-9900)

Catalog No.S1737

For research use only.

Prednisolone (NSC-9900) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.

Prednisolone (NSC-9900) Chemical Structure

CAS No. 50-24-8

Selleck's Prednisolone (NSC-9900) has been cited by 12 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective Glucocorticoid Receptor Inhibitors

Biological Activity

Description Prednisolone (NSC-9900) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.
Targets
Glucocorticoid receptor [1]
In vitro

Prednisolone (50 mg/kg, im) given 15 min before LPS-attenuated production of NO2- and NO3- by neutrophils and suppresses LPS-stimulated mRNA for NOS II in rat neutrophils. [1] Prednisolone reduces joint swelling through a mechanism associated with a reduction in IL-1beta and IL-6 protein and mRNA expression levels in SCW-induced arthritis rats. [2] Prednisolone's anti-inflammatory effects can be mediated by reducing cellular adhesion molecule (CAM) expression. Prednisolone (0.75 mg/kg) reduces macrophages (-59%, -57%), CD4(+) T-cells (-50%, -60%), CD8(+) T-cells (-58%, -48%), and eosinophils (-36%, -25%) in quadriceps and soleus muscles, respectively. Prednisolone-treated mice also exhibits decreased vascular P-selectin (-82%) and ICAM-1 (-52%) expression and fewer L-selectin (-79%) and ICAM-1 (-57%) expressing mononuclear cells in quadriceps. Prednisolone reduces sarcolemmal damage and degeneration as well in Dystrophin-deficient, mdx mice. [3]

In vivo Prednisolone (5 mg/kg) causes alterations in diaphragmatic contractile properties and histological changes without fiber atrophy in rats. Prednisolone results in an increased number of diaphragmatic bundles in rats. [4] Prednisolone induces a significant decline of PL-pO2, while CoBF, CMs, CAPs, and ABRs revealed no change in guinea pigs. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 360.44
Formula

C21H28O5

CAS No. 50-24-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04560582 Not yet recruiting Procedure: Blood Draw Kidney Transplant; Complications|Kidney Transplant Rejection|Kidney Transplant Failure University of Minnesota August 31 2022 --
NCT05341401 Not yet recruiting Drug: Budesonide MMX|Drug: Prednisolone Ulcerative Colitis Chronic Assiut University June 2022 Phase 2|Phase 3
NCT05435781 Recruiting Drug: Hydrocortisone|Drug: Placebo for hydrocortisone Adrenal Insufficiency|Polymyalgia Rheumatica|Giant Cell Arteritis Ulla Feldt-Rasmussen|Aarhus University Hospital|Odense University Hospital|Rigshospitalet Denmark June 7 2022 Phase 4
NCT05417906 Recruiting Other: Standard care|Other: Eosinophil-directed care Asthma Attack|Asthma Changi General Hospital|Singapore General Hospital June 2022 Phase 2
NCT04965636 Not yet recruiting Drug: Mepolizumab Hypereosinophilic Syndrome GlaxoSmithKline June 30 2022 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Prednisolone (NSC-9900) | Prednisolone (NSC-9900) ic50 | Prednisolone (NSC-9900) price | Prednisolone (NSC-9900) cost | Prednisolone (NSC-9900) solubility dmso | Prednisolone (NSC-9900) purchase | Prednisolone (NSC-9900) manufacturer | Prednisolone (NSC-9900) research buy | Prednisolone (NSC-9900) order | Prednisolone (NSC-9900) mouse | Prednisolone (NSC-9900) chemical structure | Prednisolone (NSC-9900) mw | Prednisolone (NSC-9900) molecular weight | Prednisolone (NSC-9900) datasheet | Prednisolone (NSC-9900) supplier | Prednisolone (NSC-9900) in vitro | Prednisolone (NSC-9900) cell line | Prednisolone (NSC-9900) concentration | Prednisolone (NSC-9900) nmr